What is the financial and structural nature of Bayer's deal with Apollo regarding its contraceptives unit?

Bayer secured €3 billion ($3.4 billion) in equity from Apollo-managed funds for its long-acting reversible contraceptives (LARC) business, with Apollo taking a minority, non-controlling stake in a new entity holding that business while Bayer retains majority ownership and complete operational control; the LARC business remains part of Bayer’s pharmaceuticals division, fully consolidated in its group accounts.

Why did Bayer pursue this transaction, according to its CFO, and when is it expected to close?

According to Bayer CFO Judith Hartmann, the transaction is a 'strategic financing solution' intended to strengthen the balance sheet and enhance financial flexibility amid increased liquidity requirements in 2026 related to bond maturities and litigation procedures; the deal is expected to close in the third quarter of 2026, subject to antitrust approval and customary conditions.

Bayer Secures €3 Billion from Apollo for Contraceptives Unit

Jul 9, 2026

Bayer secured €3 billion in equity from Apollo for its contraceptives unit, retaining majority control to strengthen its balance sheet against upcoming bond maturities. The transaction is expected to close in Q3 2026 pending antitrust approval.

reuters

2026-07-09

Bayer Secures €3 Billion from Apollo for Contraceptives Unit

2026-07-17

Bayer Secures €3 Billion Equity Investment from Apollo Fund

Bayer Secures €3 Billion from Apollo for Contraceptives Unit

FAQ